MedTrace Logo

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

NCT04560322 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-13

No results posted yet for this study

Summary

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The names of the study drugs involved in this study are:

* obinutuzumab
* venetoclax
* acalabrutinib

Conditions

Interventions

DRUG

Venetoclax

Tablet, taken by mouth

DRUG

Obinutuzumab

Intravenous infusion

DRUG

Acalabrutinib

Capsule, taken by mouth

Sponsors & Collaborators

Principal Investigators

  • Jacob D Soumerai, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-19
Primary Completion
2028-03-01
Completion
2029-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04560322 on ClinicalTrials.gov